These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28323660)

  • 61. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.
    Si-Tayeb K; Idriss S; Champon B; Caillaud A; Pichelin M; Arnaud L; Lemarchand P; Le May C; Zibara K; Cariou B
    Dis Model Mech; 2016 Jan; 9(1):81-90. PubMed ID: 26586530
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Common mutations of familial hypercholesterolemia patients in Taiwan: characteristics and implications of migrations from southeast China.
    Chiou KR; Charng MJ
    Gene; 2012 Apr; 498(1):100-6. PubMed ID: 22353362
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Moderate phenotypic expression of familial hypercholesterolemia in Tunisia.
    Jelassi A; Slimani A; Jguirim I; Najah M; Abid A; Boughamoura L; Mzid J; Fkih M; Maatouk F; Rouis M; Varret M; Slimane MN
    Clin Chim Acta; 2010 May; 411(9-10):735-8. PubMed ID: 20144596
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Novel LDLR variants in patients with familial hypercholesterolemia: in silico analysis as a tool to predict pathogenic variants in children and their families.
    Mollaki V; Progias P; Drogari E
    Ann Hum Genet; 2013 Sep; 77(5):426-34. PubMed ID: 23815734
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
    Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP
    Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The UCL low-density lipoprotein receptor gene variant database: pathogenicity update.
    Leigh S; Futema M; Whittall R; Taylor-Beadling A; Williams M; den Dunnen JT; Humphries SE
    J Med Genet; 2017 Apr; 54(4):217-223. PubMed ID: 27821657
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mutational heterogeneity in low-density lipoprotein receptor gene related to familial hypercholesterolemia in Morocco.
    Chater R; Aït Chihab K; Rabès JP; Varret M; Chabraoui L; El Jahiri Y; Adlouni A; Boileau C; Kettani A; El Messal M
    Clin Chim Acta; 2006 Nov; 373(1-2):62-9. PubMed ID: 16806138
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular testing for familial hypercholesterolaemia-associated mutations in a UK-based cohort: development of an NGS-based method and comparison with multiplex polymerase chain reaction and oligonucleotide arrays.
    Reiman A; Pandey S; Lloyd KL; Dyer N; Khan M; Crockard M; Latten MJ; Watson TL; Cree IA; Grammatopoulos DK
    Ann Clin Biochem; 2016 Nov; 53(6):654-662. PubMed ID: 26748104
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Differences in allele frequencies of autosomal dominant hypercholesterolemia SNPs in the Malaysian population.
    Alex L; Chahil JK; Lye SH; Bagali P; Ler LW
    J Hum Genet; 2012 Jun; 57(6):358-62. PubMed ID: 22534770
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation.
    Marduel M; Ouguerram K; Serre V; Bonnefont-Rousselot D; Marques-Pinheiro A; Erik Berge K; Devillers M; Luc G; Lecerf JM; Tosolini L; Erlich D; Peloso GM; Stitziel N; Nitchké P; Jaïs JP; ; Abifadel M; Kathiresan S; Leren TP; Rabès JP; Boileau C; Varret M
    Hum Mutat; 2013 Jan; 34(1):83-7. PubMed ID: 22949395
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment.
    Usifo E; Leigh SE; Whittall RA; Lench N; Taylor A; Yeats C; Orengo CA; Martin AC; Celli J; Humphries SE
    Ann Hum Genet; 2012 Sep; 76(5):387-401. PubMed ID: 22881376
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Familial Hypercholesterolemia in a Healthy Elderly Population.
    Lacaze P; Sebra R; Riaz M; Hooper AJ; Tiller J; Bakshi A; Woods RL; Tonkin AM; Reid CM; Murray AM; Nicholls SJ; Watts GF; Schadt E; McNeil JJ
    Circ Genom Precis Med; 2020 Aug; 13(4):e002938. PubMed ID: 32522009
    [No Abstract]   [Full Text] [Related]  

  • 74. Whole Exome/Genome Sequencing Joint Analysis of a Family with Oligogenic Familial Hypercholesterolemia.
    Ghaleb Y; Elbitar S; Philippi A; El Khoury P; Azar Y; Andrianirina M; Loste A; Abou-Khalil Y; Nicolas G; Le Borgne M; Moulin P; Di-Filippo M; Charrière S; Farnier M; Yelnick C; Carreau V; Ferrières J; Lecerf JM; Derksen A; Bernard G; Gauthier MS; Coulombe B; Lütjohann D; Fin B; Boland A; Olaso R; Deleuze JF; Rabès JP; Boileau C; Abifadel M; Varret M
    Metabolites; 2022 Mar; 12(3):. PubMed ID: 35323704
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Variability in assigning pathogenicity to incidental findings: insights from LDLR sequence linked to the electronic health record in 1013 individuals.
    Safarova MS; Klee EW; Baudhuin LM; Winkler EM; Kluge ML; Bielinski SJ; Olson JE; Kullo IJ
    Eur J Hum Genet; 2017 Apr; 25(4):410-415. PubMed ID: 28145427
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Systematic Cell-Based Phenotyping of Missense Alleles.
    Thormählen AS; Runz H
    Methods Mol Biol; 2017; 1601():215-228. PubMed ID: 28470529
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Identification and biochemical analysis of a novel APOB mutation that causes autosomal dominant hypercholesterolemia.
    Thomas ER; Atanur SS; Norsworthy PJ; Encheva V; Snijders AP; Game L; Vandrovcova J; Siddiq A; Seed M; Soutar AK; Aitman TJ
    Mol Genet Genomic Med; 2013 Sep; 1(3):155-61. PubMed ID: 24498611
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pairwise effects between lipid GWAS genes modulate lipid plasma levels and cellular uptake.
    Zimoń M; Huang Y; Trasta A; Halavatyi A; Liu JZ; Chen CY; Blattmann P; Klaus B; Whelan CD; Sexton D; John S; Huber W; Tsai EA; Pepperkok R; Runz H
    Nat Commun; 2021 Nov; 12(1):6411. PubMed ID: 34741066
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension.
    Huang Z; Xu A; Cheung BMY
    Curr Hypertens Rep; 2017 Apr; 19(4):28. PubMed ID: 28337713
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9.
    Baruch A; Luca D; Kahn RS; Cowan KJ; Leabman M; Budha NR; Chiu CPC; Wu Y; Kirchhofer D; Peterson A; Davis JC; Tingley WG
    Clin Cardiol; 2017 Jul; 40(7):503-511. PubMed ID: 28326559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.